Please login to the form below

Not currently logged in
Email:
Password:

GSK launches specialist rare diseases unit

GSK has launched a standalone unit to specialise in development and commercialisation of medicines for rare diseases

GlaxoSmithKline (GSK) has launched a standalone unit to specialise in development and commercialisation of medicines for rare diseases.

The unit will be led by Marc Dunoyer, GSK's president of Asia Pacific and chairman of Japan. Dunoyer will work closely with GSK's senior vice president of Drug Discovery, Patrick Vallance.

This specialist unit will leverage existing capabilities and partnerships, such as those made by GSK with specialist companies, Prosensa and JCR Pharmaceuticals during 2009, and will establish further in-licensing opportunities.

As part of the agreement with JCR Pharmaceuticals, a Japanese developer and manufacturer of bioactive products, GSK obtained global rights to a number of enzyme replacement therapies that could, upon approval, be used to treat orphan diseases such as Hunter syndrome, Fabry disease and Gaucher disease. 

Marc Dunoyer said: "In addition to our existing discovery effort, alternative opportunities need to be explored to make treatments available for rare diseases. This complementary approach will combine our existing global expertise with specialist partners. Over time, this new unit has the potential to deliver multiple therapies responding to high medical needs of underserved populations of patients." 

Data from Orpha.net, a portal for rare diseases and orphan drugs, shows that over 5,500 rare diseases have been identified. Of these, less than 10 per cent are currently being treated. Many rare diseases are genetic in origin, start in childhood and cause lifelong debility and premature death.

4th February 2010

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Dovetail

We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...

Latest intelligence

World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour
Strong strategising depends on your colleagues’ behaviour...
Pharmaceutical Marketing Strategies For The Digital Age
In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...